StockData
Verrica Pharmaceuticals Inc. logo

Verrica Pharmaceuticals Inc. (VRCA) stock

VRCANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$2.88+0.03 (+1.05%)

Close on Nov 19, 2026Market cap $49.56MP/E –Yield –

Verrica Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Verrica Pharmaceuticals's free cash flow for the twelve months ending Dec 31, 2025 was -$17.63M. For fiscal 2025 it was -$17.63M. The highest annual figure on record is -$17.63M in fiscal 2025.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$17.63M–
FY2024Dec 31, 2024-$60.95M–
FY2023Dec 31, 2023-$38.94M–
FY2022Dec 31, 2022-$18.95M–
FY2021Dec 31, 2021-$28.47M–
FY2020Dec 31, 2020-$31.68M–
FY2019Dec 31, 2019-$28.09M–
FY2018Dec 31, 2018-$18.65M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$4.59M–
Q3 FY2025Sep 30, 2025$9.69M–
Q4 FY2024Dec 31, 2024-$16.06M–
Q3 FY2024Sep 30, 2024-$8.57M–
Q2 FY2024Jun 30, 2024-$16.37M–
Q1 FY2024Mar 31, 2024-$19.95M–
Q4 FY2023Dec 31, 2023-$14.73M–
Q3 FY2023Sep 30, 2023-$14.88M-951.0%
Q2 FY2023Jun 30, 2023-$4.73M–
Q1 FY2023Mar 31, 2023-$4.60M–
Q4 FY2022Dec 31, 2022-$5.02M–
Q3 FY2022Sep 30, 2022$1.75M–
Q2 FY2022Jun 30, 2022-$7.34M-433.0%
Q1 FY2022Mar 31, 2022-$8.35M–
Q4 FY2021Dec 31, 2021-$8.94M–
Q3 FY2021Sep 30, 2021-$10.64M–
Q2 FY2021Jun 30, 2021$2.20M–
Q1 FY2021Mar 31, 2021-$11.10M–
Q4 FY2020Dec 31, 2020-$6.64M–
Q3 FY2020Sep 30, 2020-$7.72M–
Q2 FY2020Jun 30, 2020-$8.71M–
Q1 FY2020Mar 31, 2020-$8.61M–
Q4 FY2019Dec 31, 2019-$8.22M–
Q4 FY2018Dec 31, 2018-$7.55M–
Q3 FY2018Sep 30, 2018-$5.15M–
Q2 FY2018Jun 30, 2018-$3.77M–
Q1 FY2018Mar 31, 2018-$2.17M–

More Verrica Pharmaceuticals figures

See a number that looks wrong?